Skip to main content

ADC Therapeutics SA 8-K, filed Nov 4, 2026

ADC Therapeutics SA (ADCT)

8-K 2026-11-04 For: 2026-11-04
View Original
Added on November 04, 2026

About this 8-K

ADC Therapeutics SA filed this 8-K on November 4, 2026.

ADC Therapeutics reported ZYNLONTA trials with 88.7% ORR in LOTIS-7 and 93% in marginal zone lymphoma, plus preliminary cash of $189.2 million and an expected runway into 2029. AI summary

Items reported

  • Item 2.02: Financial results
  • Item 7.01: Regulation FD disclosure
  • Item 8.01: Other events
  • Item 9.01: Financial statements and exhibits